Skip to content

Neurocrine stays at buy at Piper ahead of April FDA date

March 7, 2017

Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Neurocrine Bio. (NASDAQ: NBIX) after he surveyed US psychiatrists and neurologists who are likely to see patients
with Tardive Dyskinesia to address common investor concerns like prescriber acknowledgement of the burden of TD and prescriber preference to treat TD symptoms.

The discussion covered attributes that prescribers find important in a TD medication making the analyst confident that physician education on the KINECT data will fuel interest in prescribing INGREZZA in an initial subgroup of patients at a level that may exceed current investor expectations.

The analyst thinks the catalyst for this could be the INGREZZA PDUFA on April 11th.

No change to the price target of $80.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: